Pfizer just paid a lot of cash to catch up in the GLP race. Why its stock is higher
(PRO Views are exclusive to PRO subscribers, giving them insight on the news of the day direct from a real investing pro. See the full discussion above.) Pfizer is spending more than $7 billion to buy biotech Metsera to try to catch cup in the obesity drug market. Investors reacted by bidding shares of Pfizer…